文献速递外周动脉疾病

他汀治疗与CRITISCH登记中严重肢体缺血患者无截肢生存的关联

Association between statin therapy and amputation-free survival in patients with critical limb ischemia in the CRITISCH registry.
PubMed 文献 · J Vasc Surg · 2017-08-12

CRITISCH前瞻性多中心登记分析1200例严重肢体缺血患者,他汀治疗组445例(37%),未用他汀组371例(31%),排除384例治疗交叉者。他汀治疗与无截肢生存(AFS)风险降低(HR 0.45;95%CI 0.34-0.63;P<.001)、死亡风险降低(HR 0.40;95%CI 0.24-0.66;P<.001)及MACCE odds降低(OR 0.41;95%CI 0.23-0.69;P=.001)相关,但与截肢率降低无关(HR 1.02;95%CI 0.67-1.56;P=.922)。

要点

  • 他汀治疗与CLI患者AFS改善及死亡、MACCE风险降低相关
  • 他汀治疗未降低截肢率
  • 他汀对AFS的获益在糖尿病、CKD及老年亚组中一致

核心结论

  • 他汀治疗与CLI患者无截肢生存率提高、死亡率和MACCE率降低相关,但未改善患肢挽救率。

研究设计与样本

  • CRITISCH为前瞻性多中心登记,分析1200例CLI患者中所有可用治疗策略的有效性。
  • 按是否接受他汀分为两组,排除治疗交叉和不依从患者,最终他汀组445例(37%)、未用他汀组371例(31%),排除384例。
  • 主要复合终点为无截肢生存(AFS),同时分析MACCE、至死亡时间和至大截肢时间。

主要发现

  • 他汀组AFS风险更低(HR 0.45;95%CI 0.34-0.63;P<.001),死亡风险更低(HR 0.40;95%CI 0.24-0.66;P<.001)。
  • 他汀组MACCE odds更低(OR 0.41;95%CI 0.23-0.69;P=.001)。
  • 他汀治疗与截肢率降低无关(HR 1.02;95%CI 0.67-1.56;P=.922)。
  • 他汀对AFS的效应在糖尿病患者(HR 0.47;95%CI 0.31-0.70;P<.001)、慢性肾脏病患者(HR 0.53;95%CI 0.32-0.87;P=.012)及>75岁患者(HR 0.40;95%CI 0.26-0.60;P<.001)中一致。
  • 他汀组AFS改善见于用抗血小板药者(HR 0.64;95%CI 0.41-0.99;P=.049)、未用抗血小板药者(HR 0.26;95%CI 0.12-0.57;P=.001)、腔内治疗后(HR 0.51;95%CI 0.34-0.76;P=.001)及旁路术后(HR 0.38;95%CI 0.21-0.68;P=.001)。

临床怎么用

  • 对CLI患者可考虑他汀治疗以改善无截肢生存并降低死亡和MACCE风险,但不应期望其降低截肢率。

局限性

  • 本研究为探索性分析,非随机对照,存在选择偏倚;治疗交叉和不依从患者被排除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Secondary prevention in patients with critical limb ischemia (CLI) is crucial for the reduction of cardiovascular morbidity and mortality. Nonetheless, current recommendations are extrapolated from other high-risk populations because of the lack of CLI-dedicated trials. The aim of this explorative study was to evaluate the association of statin therapy with the outcomes of CLI patients. METHODS: The First-Line Treatments in Patients With Critical Limb Ischemia (CRITISCH) registry is a prospective multicenter registry analyzing the effectiveness of all available treatment strategies in 1200 CLI patients. For the purposes of this analysis, patients were divided into two groups based on statin administration. Treatment crossovers and nonadherent patients were excluded from analysis. The primary composite end point of this study was the amputation-free survival (AFS). Major adverse cardiovascular and cerebral events (MACCEs), time to death, and time to major amputation were also analyzed. RESULTS: Statin therapy was applied in 445 individuals (37%), 371 (31%) patients received no statins, and 384 subjects were excluded from analysis (treatment crossovers). Patients receiving statins were more likely to be younger (P < .001) and to have a history of coronary heart disease (P < .001) or previous intervention at index limb (P < .001). Patients receiving statin therapy had a lower hazard regarding AFS (hazard ratio [HR], 0.45; 95% confidence interval [CI], 0.34-0.63; P < .001) and death (HR, 0.40; 95% CI, 0.24-0.66; P < .001) as well as lower odds of MACCE (odds ratio, 0.41; 95% CI, 0.23-0.69; P = .001). However, statin therapy was not associated with reduced amputation rates (HR, 1.02; 95% CI, 0.67-1.56; P = .922). Statin effect on AFS was consistent among diabetics (HR, 0.47; 95% CI, 0.31-0.70; P < .001), patients with chronic kidney disease (HR, 0.53; 95% CI, 0.32-0.87; P = .012), and patients older than 75 years (HR, 0.40; 95% CI, 0.26-0.60; P < .001). Statin administration was also associated with an improved AFS in patients with antiplatelet medication (HR, 0.64; 95% CI, 0.41-0.99; P = .049) and without antiplatelet medication (HR, 0.26; 95% CI, 0.12-0.57; P = .001) and after both endovascular therapy (HR, 0.51; 95% CI, 0.34-0.76; P = .001) and bypass revascularization (HR, 0.38; 95% CI, 0.21-0.68; P = .001). CONCLUSIONS: Statin therapy in CLI patients is associated with an increased AFS and lower rates of mortality and MACCEs without improving, however, the salvage rates of the affected limb.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Stavroulakis K, Borowski M, Torsello G, et al. Association between statin therapy and amputation-free survival in patients with critical limb ischemia in the CRITISCH registry. J Vasc Surg. 2017. PMID: 28807382. doi:10.1016/j.jvs.2017.05.115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。